Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Akebia Therapeutics (AKBA) Long-Term Debt Repayments (2016 - 2025)

Historic Long-Term Debt Repayments for Akebia Therapeutics (AKBA) over the last 7 years, with Q1 2025 value amounting to $462000.0.

  • Akebia Therapeutics' Long-Term Debt Repayments fell 9874.2% to $462000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $461000.0, marking a year-over-year decrease of 9897.78%. This contributed to the annual value of $37.1 million for FY2024, which is 1593.44% up from last year.
  • As of Q1 2025, Akebia Therapeutics' Long-Term Debt Repayments stood at $462000.0, which was down 9874.2% from -$1000.0 recorded in Q4 2024.
  • Akebia Therapeutics' 5-year Long-Term Debt Repayments high stood at $36.7 million for Q1 2024, and its period low was -$1000.0 during Q4 2024.
  • Moreover, its 4-year median value for Long-Term Debt Repayments was $8.0 million (2023), whereas its average is $12.8 million.
  • Over the last 5 years, Akebia Therapeutics' Long-Term Debt Repayments had its largest YoY gain of 12953.75% in 2024, and its largest YoY loss of 10001.25% in 2024.
  • Over the past 4 years, Akebia Therapeutics' Long-Term Debt Repayments (Quarter) stood at $33.0 million in 2022, then plummeted by 75.76% to $8.0 million in 2023, then tumbled by 100.01% to -$1000.0 in 2024, then soared by 46300.0% to $462000.0 in 2025.
  • Its Long-Term Debt Repayments stands at $462000.0 for Q1 2025, versus -$1000.0 for Q4 2024 and $374000.0 for Q2 2024.